$Werewolf Therapeutics (HOWL.US)$Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
Werewolf Therapeutics has announced new data from their Phase 1/1b trial of WTX-124, an IL-2 INDUKINETM molecule, in patients with solid tumors. The data, presented at ASCO 2024, highlight WTX-124's clinical activity and tolerability, both as a monotherapy and in combination with pembrolizumab. Three obje...